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Abstract
Purpose: Vosaroxin is a first in class naphthyridine analog structurally related to quinolone antibacterials, that
intercalates DNA and inhibits topoisomerase II. Vosaroxin is not a P-glycoprotein receptor substrate and its activity
is independent of p53, thus evading common drug resistance mechanisms. To evaluate vosaroxin as a clinically
applicable radiation sensitizer, we investigated its effects on tumor cell radiosensitivity in vitro and in vivo.
Methods: Vosaroxin’s effect on post-irradiation sensitivity of U251, DU145, and MiaPaca-2 cells was assessed by
clonogenic assay. Subsequent mechanistic and in vivo studies were performed with U251 cells. Cell cycle
distribution and G2 checkpoint integrity was analyzed by flow cytometry. DNA damage and repair was evaluated
by a high throughput gamma-H2AX assay. Apoptosis was assessed by flow cytometry. Mitotic catastrophe was
assessed by microscopic evidence of fragmented nuclei by immunofluorescence. In vivo radiosensitization was
measured by subcutaneous tumor growth delay.
Results: 50-100 nmol/L treatment with vosaroxin resulted in radiosensitization of all 3 cell lines tested with a dose
enhancement factor of 1.20 to 1.51 measured at a surviving fraction of 0.1. The maximal dose enhancement was
seen in U251 cells treated with 75 nmol/L vosaroxin (DEF 1.51). Vosaroxin exposure did not change cell cycle
distribution prior to irradiation nor alter G2 checkpoint integrity after irradiation. No difference was seen in the
apoptotic fraction regardless of drug or radiation treatment. The number of cells in mitotic catastrophe was
significantly greater in irradiated cells treated with vosaroxin than cells receiving radiation only at 72 hr (p = 0.009).
Vosaroxin alone did not significantly increase mitotic catastrophe over control (p = 0.53). Cells treated with
vosaroxin and radiation maintained significantly higher gamma-H2AX levels than cells treated with vehicle control
(p = 0.014), vosaroxin (p = 0.042), or radiation alone (p = 0.039) after 24 hr. In vivo tumor growth delay was 1.5
days for vosaroxin alone (IV 10 mg/kg), 1.0 days for radiation (3 Gy) alone, and 8.6 days for the group treated with
vosaroxin 4 hours prior to radiation.
Conclusions: Vosaroxin enhanced tumor cell radiosensitivity in vitro and in vivo. The mechanism appears to be
related to inhibition of DNA repair and increased mitotic catastrophe.
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Introduction
Topoisomerase II inhibitors are a diverse class of anti-
cancer drugs that include the anthracyclines (doxorubicin
and daunorubicin), etoposide and quinolones[1]. Anthra-
cyclines have effective and broad-spectrum anti-tumor
activity but their clinical utility is frequently limited by
systemic toxicity (i.e. cardiotoxicity with doxorubicin) or
drug resistance (frequently mediated by p-glycoprotein).
Several topoisomerase II inhibitors are known to potenti-
ate the effects of radiation on tumor cells although the
mechanisms of radiation sensitization remain an area of
research[2-4].
Vosaroxin (Figure 1) is a naphthyridine analog struc-
turally related to quinolone antibacterials, that interca-
lates DNA and inhibits topoisomerase II. Formerly
known as voreloxin or SNS-595, it is the first drug in
this class to be investigated as an anti-cancer agent. The
drug’s mechanism of action is similar to anthracyclines,
involving intercalation of DNA and topoisomerase II
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[5]. However, vosaroxin does not have known cardio-
toxicity, is not a substrate for P-glycoprotein drug
pumps, and has p53 independent activity. Vosaroxin has
been shown to be active against various in vitro and in
vivo tumor models including breast, bladder, pancreas,
colon, ovarian, gastric, and lung cancer [6]. It has also
shown synergistic activity with platinum agents, anthra-
cyclines, antimetabolites, and targeted therapies in
tumor models [6,7]. As an initial step in evaluating
vosaroxin as a clinically applicable radiation sensitizer,
we investigated the effects of vosaroxin on the radiosen-
sitivity of a panel of human tumor cell lines. The data
indicate that vosaroxin enhances tumor cell radiore-
sponse in vitro and in vivo. Moreover, the mechanism
appears to involve the inhibition of DNA double strand
break repair.
Materials and methods
Cell lines and treatment
DU145 prostate carcinoma cells, MiaPaCa-2 pancreatic
carcinoma cells, and U251 glioblastoma cells obtained
from the ATCC were used for clonogenic assay experi-
ments and U251 cells were used in subsequent experi-
ments to investigate the mechanisms of radiosensitization.
Cells were grown in DMEM (Invitrogen) supplemented
with 10% fetal bovine serum and maintained at 37°C in a
5% CO2 atmosphere. Vosaroxin, provided by Sunesis, was
reconstituted in DMSO (10 mmol/L) and stored in the
dark at room temperature. For all studies, the working
concentration of DMSO was < 0.1%. Cultures were irra-
diated at a dose rate of 2.28 Gy/min by a Pantak X-ray
source.
Clonogenic assay
Cultures were trypsinized to generate a single-cell sus-
pension. A specified number of cells were seeded into
each well of six-well tissue culture plates. Cells were
allowed to attach for 6 hours followed by treatment
with vehicle control or vosaroxin and were irradiated 16
hours later. Ten to fourteen days after seeding the cells,
colonies were stained with crystal violet and the number
of colonies containing at least 50 cells was determined.
The surviving fractions were calculated and survival
curves generated after normalizing for cytotoxicity from
vosaroxin treatment alone.
Cell cycle analysis
Evaluation of the cell cycle and G2-checkpoint integrity
was performed by flow cytometry. Cells grown in 100
mm
2 culture dishes were exposed to vehicle control or
vosaroxin for 16 hours prior to administration of 2 Gy or
sham radiation. Cells were trypsinized 1, 3, 6, and 24
hours later, then fixed and stained per manufacturer’s
instructions with Cell Cycle Reagent and analyzed on an
EasyCyte Plus flow cytometer (Guava Technologies, Hay-
ward, CA). G2-checkpoint integrity was evaluated as pre-
viously reported by Xu, et al. [8,9] utilizing rabbit
polycolonal antibody against phospho-H3 histone (Milli-
pore) followed by staining with a goat anti-rabbit-FITC
conjugated secondary antibody (Jackson ImmunoRe-
search) to distinguish mitotic cells.
Apoptotic cell death
Apoptotic fraction was evaluated by flow cytometry using
the Guava Nexin assay. Cells grown in 100 mm
2 culture
dishes were exposed to vehicle control or vosaroxin, for
16 hours prior to administration of 2 Gy or sham radia-
tion. Cells were trypsinized and stained 24 and 72 hours
after radiation per manufacturer’s instructions with
Nexin Reagent to assess annexin V-PE as a marker of
cells in early apoptosis and 7-AAD as an indicator of late
apoptosis (Guava Technologies, Hayward, CA). Analysis
was performed on an EasyCyte Plus flow cytometer. Posi-
tive controls were treated 24 hours with 0.5 μM stauros-
porine (Sigma).
Mitotic catastrophe
The presence of fragmented nuclei was used to define cells
undergoing mitotic catastrophe. Cells were grown on
4-well chamber slides. Cells were fixed with methanol for
15 minutes at -20°C, blocked with 1% BSA, and stained
o v e r n i g h ta t4 ° Cw i t hm o u s ea n t i - a-tubulin antibody
(Sigma) followed by staining with goat anti-mouse-Texas
Red antibody (Jackson ImmunoResearch) 2 hours at room
temperature. Nuclei were counterstained with DAPI
(Sigma). Coverslips were mounted with VectaShield anti-
fade solution (Vector Labs) and were visualized on a Leica
DMRXA fluorescent microscope with a 20x objective
(Wetzlar, Germany). Digital images were captured by a
MicroPublisher 3.3 camera (QImaging, Surrey, Canada)
and overlaid in Adobe Photoshop CS (San Jose, CA). Nor-
mal cells and cells in mitotic catastrophe were manually
Figure 1 Chemical structure of vosaroxin.
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lobes as the criteria for defining cells undergoing mitotic
catastrophe. For each treatment condition 150-200 cells
were scored.
Electrochemiluminescent gamma-H2AX assay
A previously validated electrochemiluminescent assay
was used to measure gamma-H2AX levels [10]. Cells
were grown and treated on 150 mm
2 plates. Cells were
exposed to vehicle control or vosaroxin, for 16 hours
prior to administration of 2 Gy or sham radiation. 1, 6,
and 24 hours later, cells were harvested and scraped into
PBS, washed, and pelleted by centrifugation at 100 rela-
tive centrifugal force for 10 minutes. The PBS superna-
tant was discarded and the cell pellet was frozen at -80°C
overnight. Cells were resuspended in lysis buffer of NaCl
(500 mM), EDTA (2 mM), Triton X-100 (1%), sodium
deoxycholate (1%), SDS (1%), Tris HCl (50 mM), NaF
(10 mM), phosphatase and protease inhibitors (1 ×), and
PMSF (2 mM). Proteins were solubilized by sonication
and protein concentration was determined by Bradford
assay. 5 μg of protein from each cell lysate was coated
onto a 96-well plates and left overnight. Wells were
blocked with 3% blocking solution, washed, and a sulfo-
ester tag conjugated phospho-H2AX (Abcam) detection
antibody was added in 1% blocking solution (1 μg/ml).
Wells were washed thrice with TBS. A read buffer was
added before analysis in an electrochemiluminescent
imager (Meso Scale Discovery).
In vivo subcutaneous tumor growth delay assay
Four to six week old, female, athymic NCr nu/nu,n u d e
mice (NCI Animal Production Program, Frederick, MD)
were used for all in vivo studies. Animals were caged in
groups of 5 or less and were fed animal chow and water
ad libitum. A single cell suspension (10 × 10
6) of U251
cells was implanted on the lateral aspect of the rear leg.
When tumors reached ≈ 100 mm
3 ([L × W
2]/2)a n i m a l s
were randomized to four groups including untreated
controls, vosaroxin (10 mg/kg IV into tail vein), irradia-
tion alone (3 Gy), or vosaroxin + irradiation (10 mg/kg
IV into tail vein + 3 Gy). Irradiation of tumors took place
4 hours after treatment with vosaroxin based on sus-
pected drug metabolism in vivo, with animals restrained
in lead jigs custom made by the Radiation Biology Branch
of the National Cancer Institute. Tumors were measured
three times per week until they reached ≥ 1000 mm
3.
Specific tumor growth delay was calculated for individual
animals. The growth delay for the group was calculated
as the mean number of days to reach 1,000 mm
3 in the
treatment group minus the mean number of days for the
control group to reach the same size. Group means ±
standard error are reported. Each experimental group
contained 6 animals. All animal studies were conducted
in accordance with the principles and procedures out-
lined in the NIH Guide for the Care and Use of Animals.
Statistical analysis
In vitro studies were subject to three independent
experiments. Data is presented as mean ± SE. A Stu-
dent’s t test was used to compare sample means with a
p value of < 0.05 considered significant.
Results
To determine the effects of vosaroxin on the radiosensi-
tivity of tumor cells, a clonogenic assay was performed.
The previously reported average IC50 value for vosaroxin
alone in 20 cancer cell lines was 322 nmol/L [6]. As
drug exposure times are longer during clonogenic survi-
val studies with radiation, concentrations from 50 nmol/
L to 100 nmol/L of vosaroxin were used.
Treatment of U251 cells with vosaroxin at 50 nmol/L
and 75 nmol/L yielded a surviving fraction of 0.73 ±
0.075 and 0.77 ± 0.16 respectively which is an appropri-
ate degree of cytotoxicity for evaluation in combination
with radiation. In the combination protocol, 16 hours
after drug was added, cells were irradiated and colony
forming efficiency was determined 10-14 days later. This
treatment resulted in a dose enhancement factor of 1.33
and 1.51 for 50 nmol/L and 75 nmol/L, respectively, at
a surviving fraction of 0.10. The clonogenic assay was
repeated with DU145 and MiaPaca-2 cells. These cell
lines also showed radiosensitization with dose enhance-
ment factors of 1.20-1.35 at 50-100 nmol/L. Cytotoxicity
was found to be greater at 100 nmol/L than 50 nmol/L
in these cell lines (surviving fraction of 0.22-0.26 vs.
0.68-0.69) in DU145 and MiaPaca-2. The survival curves
and a table summarizing the results from the clonogenic
assays are shown in Figure 2
To begin to assess the cellular mechanisms or processes
through which vosaroxin enhanced radiosensitivity, we
focused on 75 nmol/L exposures in U251 cell lines due to
the low cytotoxicity observed and the high dose enhance-
ment factor. Cell cycle analysis was performed to deter-
mine if the drug exposure had resulted in accumulation of
cells in a radiosensitive phase of the cell cycle. After a 16
hour incubation with 75 nM of vosaroxin alone, no differ-
ence in the ratio of cells in G1, S, or G2-M phase was seen
(data not shown). Another potential source of radiosensiti-
zation is the abrogation of the G2 checkpoint after irradia-
tion. To distinguish mitotic cells from G2 cells which both
have 4 N DNA content and are not distinguished by pro-
pidium iodine staining, an antibody against phosphory-
lated histone H3 was used to detect mitotic cells as
histone H3 is exclusively phosphorylated during mitosis,
using the method of Xu [8,9]. As expected, the mitotic
index (percentage of cells in mitosis), significantly
decreased at 1 and 3 hours after radiation and then
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the normal G2 checkpoint activation initiated after radia-
tion damage. In cells treated with the combination of
vosaroxin and radiation, cell cycle distribution was the
same as in the cells treated with radiation alone (signifi-
cantly decreased mitotic index at 1 and 3 hours with
return to baseline by 6 hours), indicating that there was
no bypass of the G2 checkpoint (Figure 3). These results
indicate that the radiation sensitization induced by vosar-
oxin is neither due to drug-induced alterations in cell
cycle distribution at the time of irradiation nor due to
abrogation of the G2 checkpoint after irradiation.
To provide insight into the mechanism of radiosensiti-
zation, we then determined the mode of cell death. At
micromolar doses, vosaroxin has been shown to cause
apoptosis in several cancer cell lines [5,11]. To deter-
mine if the 75 nM concentration of vosaroxin used in
this study was inducing apoptosis after radiation, flow
cytometry was performed. Less than 2% of cells in all
treatment groups were apoptotic at 24 and 72 hours
with no difference seen between untreated controls and
cells treated with 75 nmol/L vosaroxin, 2 Gy, or the
combination of 2 Gy and 75 nmol/L vosaroxin (data not
shown).
To assess the effects of vosaroxin treatment on DNA
damage and repair, a high throughput electrochemilumi-
nescent assay to detect gamma-H2AX levels in cells was
used to measure DNA double strand breaks at 1, 6 and
24 hours (Figure 4). Vosaroxin alone caused no change
in gamma-H2AX levels. At one hour, cells treated with
radiation or the combination of vosaroxin and radiation
had significantly higher gamma-H2AX levels compared
to control or drug treated cells (< 0.001). At one hour,
cells treated with both drug and radiation had higher
mean gamma-H2AX levels than cells that were irra-
diated only (739.6 ± 70.7 and 582.4 ± 59.6) but this was
not a significant difference (p = 0.11). At 6 hours, there
was also no significant difference between cells treated
with radiation alone versus vosaroxin and radiation (p =
0.47). As expected, at 24 hours, the cells treated with
radiation alone had returned to baseline gamma-H2AX
levels. However, the cells treated with vosaroxin and
radiation maintained significantly higher gamma-H2AX
levels than the cells treated with vehicle control (p =
0.014), vosaroxin (p = 0.042), or radiation alone (p =
0.039). The significant elevation of gamma-H2AX levels
at 24 hours in the combination group compared to the
other 3 groups suggests that vosaroxin inhibited DNA
double strand break repair.
Since vosaroxin inhibits DSB repair and does not cause
a significant increase in radiation induced apoptosis, we
hypothesized that vosaroxin may induce radiosensitiza-
tion through an enhancement of cells undergoing mitotic
catastrophe. To assess mitotic catastrophe, the presence
Figure 2 Vosaroxin enhances radiation sensitivity in tumor cell lines. The effects of vosaroxin on radiosensitivity by clonogenic assay. Cells
were seeded as a single-cell suspension with a specified number of cells. After allowing cells time to attach (6 h), vosaroxin or the vehicle
control was added at specified concentrations and the plates were irradiated 16 h later. Ten to fourteen days after seeding, survival curves were
generated after normalizing for the cytotoxicity generated by vosaroxin alone. Figure shows U251 (A), DU145 (B), MiaPaca-2 (C), and a table
showing cytotoxicity of vosaroxin alone and the radiation dose enhancement factor (DEF) for each cell line and drug dose combination (D).
Data presented are the mean ± SE from at least three independent experiments.
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cence. As shown in Figure 5, the number of cells in mito-
tic catastrophe was significantly greater in irradiated cells
treated with vosaroxin than cells receiving radiation only
at 72 (p = 0.009) post-irradiation. There was no signifi-
cant difference at 24 and 48 hours. Vosaroxin alone
caused no significant increase in mitotic catastrophe over
control cells at any time points (p = 0.53).
The in vitro data presented above indicate that vosar-
oxin enhances the radiosensitivity of U251 glioma cells
and that the mechanism involves the inhibition of DSB
repair. To assess the effect on tumors in an in vivo
model, mice bearing U251 subcutaneous xenografts were
randomized into four groups: vehicle, vosaroxin (10 mg/
kg), irradiation alone (3 Gy), and vosaroxin and irradia-
tion (10 mg/kg and 3 Gy). The average tumor sizes for
the U251 tumors exposed to each treatment are shown
in Figure 6. The average initial tumor volume was 172 ±
5m m
3 with no significant differences in average initial
size between groups. For each group, time to grow to
1,000 mm
3 (a 5-fold increase in tumor size) was calcu-
lated using the tumor volumes from each individual mice
in each group (mean ± SE). The time for the tumor to
grow from 172 to 1,000 mm
3 increased from 15.8 ± 0.8
days for vehicle-treated mice to 18.7 ± 4.3 days for vosar-
oxin-treated mice. Irradiated mice reached 1,000 mm
3 in
16.8 ± 3.5 days; mice treated with radiation and vosaroxin
reached 1,000 mm
3 in 24.4 ± 1.0 days. The absolute
growth delays (the time in days for tumors in treated
Figure 3 Cell cycle distribution and mitotic index after irradiation is not altered by vosaroxin. The percentage of cells in G0/G1, S, and
G2/M phase of the cell cycle before and after radiation (2 Gy) with and without vosaroxin treatment (75 nmol/L). There was no difference in
(3A) cell cycle distribution or (3B) mitotic index with vosaroxin treatment. *, p < 0.05 comparing mitotic index at 1 and 3 hours after radiation to
baseline.
Figure 4 Vosaroxin increases gamma-H2AX retention at 24
hours after irradiation. A high throughput
electrochemiluminescent assay to detect gamma-H2AX staining
intensity was performed. Cells were plated in 100-mm cell culture
dishes, allowed to attach (6 hr) and then incubated in vosaroxin (75
nmol/L) or vehicle containing media (16 hr) prior to irradiation (2
Gy). Cells were harvested at specified time points and stained with
sulfo-ester tag conjugated phospho-H2AX detection antibody and
luminescence was detected by an electrochemiluminescent imager.
Data presented are the mean ± SE from at least three independent
experiments. *, p < 0.05 comparing both radiation alone and
vosaroxin alone treated cells to the combination treatment.
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3 minus the time in
days for tumors to reach the same size in vehicle-treated
mice) were 2.9 days for vosaroxin alone, 1.0 days for
radiation alone, and 8.7 days for vosaroxin plus radiation
therapy. Therefore the combination treatment group
produced a tumor growth delay greater than the sum of
the drug and radiation treatments alone (p = 0.004).
These data indicate that vosaroxin enhances the radiation
induced tumor growth delay of U251 xenografts.
Discussion
This study demonstrated the enhanced radiosensitivity of
human tumor cells after exposure to vosaroxin, an agent
that acts as a DNA intercalator and an inhibitor of topoi-
somerase II. The potential of topoisomerase II as a target
for radiosensitization has been previously suggested in
studies with other agents in experimental tumor models.
[2-4] Etoposide is a non-intercalating topoisomerase II
inhibitor that enhances radiosensitivity due to effects on
radiation repair and cell cycle [2,12]. The role of cell
cycle in radiosensitization by topoisomerase inhibitors is
complex. The mechanisms of radiation sensitization are
important considerations because they influence the
maximal cytotoxicity achieved in a time and sequence
specific manner [4]. Radiation causes cells to arrest in
G2/M phase which is when topoisomerase II typically
functions as an important repair enzyme. Conversely,
topoisomerase II inhibitors can cause G2 arrest which
places cells in a relatively radiosensitive phase of the cell
cycle [13]. However, in this study, G2 arrest was not seen
at the doses of vosaroxin used. Therefore, this does not
appear to be the mechanism of radiosensitization in this
study.
The data presented here indicate that there was no sig-
nificant initial increase in DNA damage based on
gamma-H2AX levels at early time points after radiation
suggesting no increase in the number of DNA-DSBs.
However, at 24 hours after radiation, there was increased
gamma-H2AX foci retention suggesting vosaroxin inhi-
bits the repair of radiation induced DNA damage in
U251 cells. Mechanistic conclusions made here are based
only on one cell line and the mechanism of action of
vosaroxin radiosensitization may differ among cell types.
In addition, the potential for normal tissue radiosensitiza-
tion will need to be considered in future work. A pre-
vious study evaluating the topoisomerase II inhibitors
amrubicin and amrubicinol in lung adenocarcinoma
showed similar enhancement of radiosensitivity to the
results reported here with enhancement ratios of 1.38
and 1.57[3]. Similar to our findings, this study showed no
increase in apoptosis when cells were irradiated and trea-
ted with topoisomerase inhibitors. The study found an
increased proportion of necrotic cells after radiation and
drug treatment with sub-additive increases in percent
necrosis in the combination treated cells [3].
This data provides support for further evaluation of
vosaroxin as a radiation sensitizer. As the first study to
evaluate the radiation sensitizing properties of vosaroxin,
this provides a basis for additional preclinical exploration
Figure 5 Mitotic catastrophe after irradiation increases at
72 hours with vosaroxin treatment. U251cells growing in chamber
slides were exposed to vosaroxin (75 nmol/L) for 16 h, irradiated (2 Gy),
and fixed at 24 h to 72 hours after irradiation for immunocytochemical
analysis of mitotic catastrophe. Nuclear fragmentation (defined as the
presence of two or more distinct lobes within a single cell) was
evaluated in at least 150 cells per treatment per experiment. * = p <
0.05 comparing cells in the combination group compared to either
drug or radiation alone groups at the same time point.
Figure 6 Vosaroxin causes a greater than additive increase in
tumor growth delay. Mice were implanted with 1 × 10
6 U251cells
on the lateral aspect of the rear leg. Tumors were randomized at
172 mm
3 into four groups and treated with either vehicle control,
vosaroxin alone (10 mg/kg by tail vein injection), radiotherapy (3
Gy), vosaroxin/3 Gy. Tumors were measured three times per week
and followed until they reached at least 1,000 mm
3. Volumes were
calculated using the formula (L × W × W)/2.
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thorough investigation and understanding of the specific
molecular mechanisms leading to radiosensitization is
warranted as these pathways were not identified in this
study.
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